NZ546062A - Prevention and treatment of inflammation-induced and/or immune-mediated bone loss - Google Patents

Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Info

Publication number
NZ546062A
NZ546062A NZ546062A NZ54606204A NZ546062A NZ 546062 A NZ546062 A NZ 546062A NZ 546062 A NZ546062 A NZ 546062A NZ 54606204 A NZ54606204 A NZ 54606204A NZ 546062 A NZ546062 A NZ 546062A
Authority
NZ
New Zealand
Prior art keywords
formula
type
bone
alkyl
hsd
Prior art date
Application number
NZ546062A
Other languages
English (en)
Inventor
Thomas Wilckens
Ariane Volkmann
Original Assignee
Onepharm Res And Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onepharm Res And Dev Gmbh filed Critical Onepharm Res And Dev Gmbh
Publication of NZ546062A publication Critical patent/NZ546062A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Veneer Processing And Manufacture Of Plywood (AREA)
  • Steroid Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
NZ546062A 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss NZ546062A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50471703P 2003-09-22 2003-09-22
PCT/EP2004/010582 WO2005027882A1 (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Publications (1)

Publication Number Publication Date
NZ546062A true NZ546062A (en) 2009-09-25

Family

ID=34375537

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ546062A NZ546062A (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Country Status (15)

Country Link
US (2) US20100087413A1 (cg-RX-API-DMAC7.html)
EP (2) EP2036548A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007533625A (cg-RX-API-DMAC7.html)
AT (1) ATE416761T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004273610B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539741A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111246T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004018338D1 (cg-RX-API-DMAC7.html)
DK (1) DK1663185T3 (cg-RX-API-DMAC7.html)
ES (1) ES2317029T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ546062A (cg-RX-API-DMAC7.html)
PL (1) PL1663185T3 (cg-RX-API-DMAC7.html)
PT (1) PT1663185E (cg-RX-API-DMAC7.html)
SI (1) SI1663185T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005027882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005279845A1 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using RNase H inhibitors
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
EP1864668B1 (en) * 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
AU2007271182B2 (en) 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
KR101022809B1 (ko) * 2008-02-05 2011-03-17 재단법인서울대학교산학협력재단 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료
JP5637562B2 (ja) * 2008-09-25 2014-12-10 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
SI2640467T1 (sl) 2010-11-19 2015-04-30 Novartis Ag Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
AU2014272695B2 (en) 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
CN104873521A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN111386279A (zh) 2017-08-04 2020-07-07 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
GB201805100D0 (en) * 2018-03-28 2018-05-09 Benevolentai Bio Ltd Treatment of sarcopenic diseases
JP7735185B2 (ja) * 2019-02-07 2025-09-08 アルデリックス, インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
EP4754084A1 (de) * 2023-07-28 2026-06-10 Symrise AG Heterozyklische verbindungen als physiologische kühlstoffe

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262851A (en) * 1958-06-26 1966-07-26 Biorex Laboratories Ltd Pharmacological compositions containing glycyrrhetinic acid derivative
DE2050072C3 (de) * 1970-10-12 1975-01-30 Inverni Della Beffa S.P.A., Mailand (Italien) Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
GB2261672A (en) * 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
DE19951970A1 (de) * 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
IL161154A0 (en) 2001-11-22 2004-08-31 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP2380899A1 (en) 2002-09-23 2011-10-26 E. I. du Pont de Nemours and Company Isolation and use of ryanodine receptors
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1663185B1 (en) 2008-12-10
CY1111246T1 (el) 2015-06-11
ES2317029T3 (es) 2009-04-16
WO2005027882A1 (en) 2005-03-31
US20100087413A1 (en) 2010-04-08
CA2539741A1 (en) 2005-03-31
DK1663185T3 (da) 2009-04-06
EP1663185A1 (en) 2006-06-07
PL1663185T3 (pl) 2009-06-30
AU2004273610A1 (en) 2005-03-31
EP2036548A1 (en) 2009-03-18
ATE416761T1 (de) 2008-12-15
SI1663185T1 (sl) 2009-04-30
US20110275584A1 (en) 2011-11-10
JP2007533625A (ja) 2007-11-22
AU2004273610B2 (en) 2010-07-01
DE602004018338D1 (de) 2009-01-22
PT1663185E (pt) 2009-02-16

Similar Documents

Publication Publication Date Title
AU2004273610B2 (en) Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
CA2559408C (en) Carboline derivatives useful in the inhibition of angiogenesis
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
CA3183081A1 (en) Combination therapy for treatment of cancer
AU2007349112A1 (en) Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
WO1998002151A2 (en) Chemokine receptor antagonists and methods of use therefor
AU2006310518A1 (en) Pharmaceutical use of substituted amides
JPH10511682A (ja) ジドブジン、1592u89および3tcまたはftcの相乗的組み合わせ
AU2007276804A1 (en) Inhibitors of undecaprenyl pyrophosphate synthase
ES2685923T3 (es) Composición medicinal para mejorar la función cerebral
KR20170131650A (ko) 글루타미나제 억제제의 투여 방법
JP2000507224A (ja) Csaid化合物の血管形成の抑制物質としての使用
SK170999A3 (en) Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent
EA019919B1 (ru) Способ подавления роста или метастазирования ангиогенез-зависимой опухоли
US20080194548A1 (en) Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
KR20050021497A (ko) 피페리딘 유도체 및 MIP-1α 수용체 CCR1에결합하는 MIP-1α의 선택적 길항제로서의 그들의 용도
WO2001064213A1 (en) Compounds and methods
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
JPH10511978A (ja) アルツハイマー病の治療用薬剤
WO2006016689A1 (ja) Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤
HU210257B (en) Process for the preparation of pharmaceutical composition with anti-herpes effect containing castanospermine esters
JP2002348288A (ja) スピロ複素環誘導体およびそれらを有効成分とする薬剤
KR101492552B1 (ko) 요 배출 장애 치료제
KR102905321B1 (ko) 구강 건조증의 치료에 사용하기 위한 화합물
JPWO2004092136A1 (ja) 含窒素複素環化合物およびその用途

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ONEPHARM RESEARCH AND DEVELOPMENT GMBH, AT

Free format text: OLD OWNER(S): BIONETWORKS GMBH; ARIANE VOLKMANN

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: THE NAME OF THE APPLICANTS (71) AND INVENTORS (72) HAVE BEEN CORRECTED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)